Provided by Tiger Trade Technology Pte. Ltd.

Verastem

7.08
+0.22003.21%
Volume:66.83K
Turnover:469.36K
Market Cap:641.19M
PE:-2.93
High:7.11
Open:6.93
Low:6.90
Close:6.86
52wk High:11.25
52wk Low:3.43
Shares:90.56M
Float Shares:70.57M
Volume Ratio:0.95
T/O Rate:0.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4143
EPS(LYR):-3.0223
ROE:-471.16%
ROA:-49.59%
PB:12.83
PE(LYR):-2.34

Loading ...

Verastem Is Maintained at Buy by BTIG

Dow Jones
·
May 08

Verastem price target raised to $18 from $16 at Alliance Global

TIPRANKS
·
May 08

H.C. Wainwright Keeps Their Buy Rating on Verastem (VSTM)

TIPRANKS
·
May 08

Verastem Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 08

Verastem Q1 adjusted loss narrows smaller than expected on recording revenue

Reuters
·
May 08

Verastem Q1 FY26 net loss narrows to $36.6 million; revenue turns to $18.7 million

Reuters
·
May 08

Verastem Q1 Adj. EPS $(0.43) Beats $(0.46) Estimate, Sales $18.671M Miss $21.579M Estimate

Benzinga Earnings
·
May 08

BRIEF-Verastem Q1 Net Income USD -36.591 Million

Reuters
·
May 08

Verastem Q1 Operating Expenses USD 63.568 Million

THOMSON REUTERS
·
May 08

Mizuho Securities Adjusts Verastem Price Target to $16 From $18, Maintains Outperform Rating

MT Newswires Live
·
Apr 30

Verastem Price Target Maintained With a $19.00/Share by BTIG

Dow Jones
·
Apr 23

Verastem Oncology to report quarterly results, host conference call and webcast

Reuters
·
Apr 23

Press Release: Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026

Dow Jones
·
Apr 23

Buy Rating on Verastem: Favorable Risk‑Reward for VS‑7375 Driven by Superior Early Efficacy vs. Zoldonrasib and Improving Safety Outlook

TIPRANKS
·
Apr 21

Verastem Price Target Maintained With a $19.00/Share by BTIG

Dow Jones
·
Apr 21

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sundrug Co (OtherSDGCF) and Verastem (VSTM)

TIPRANKS
·
Apr 13

Verastem Price Target Maintained With a $18.00/Share by HC Wainwright & Co.

Dow Jones
·
Apr 11

Verastem Says Avmapki, Fakzynja Combination Sustains Benefits for 2 Years in Ovarian Cancer

MT Newswires Live
·
Apr 10

BRIEF-Verastem Oncology Announces Two-Year Median Follow-Up Data On Avmapki® Fakzynja® Combination Therapy

Reuters
·
Apr 10

Verastem says RAMP 201 shows durable benefit for AVMAPKI-FAKZYNJA in recurrent ovarian cancer

Reuters
·
Apr 10